November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

by | Dec 8, 2021

November 2021 Top Biopharma Deal Upfront

Owkin discovery and development deal with Sanofi for AI models for cancer

Announced: November 18, 2021

Total Deal Value: $270M + Mst

Upfront Cash: none

Upfront Equity: $180M

R&D Funding: $90M over 3 years

Milestones: undisclosed R&D Mst

Royalty: n/a

Cost and Profit Split: n/a

The Asset:

Owkin’s artificial intelligence and federated learning platform to support digital clinical research in Sanofi’s core oncology efforts in 4 different cancers.

Deal Structure:

R&D Only

Partnership Features:

Collaborative Development, Funded R&D

The Details:

  • Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.
  • Sanofi will apply Owkin’s artificial intelligence (AI) and federated learning platform to advance its oncology pipeline, which includes non-small cell lung cancer (NSCLC), triple-negative breast cancer, mesothelioma, and multiple myeloma. This research partnership agreement will allow Sanofi to work closely with Owkin to identify new oncology treatments across 4 cancers.
  • Sanofi will use the Owkin platform to find new biomarkers and therapeutic targets, build prognostic models, and predict response to treatment from multimodal patient data.
  • Owkin’s global research network is powered by federated learning, which allows data scientists to securely connect to decentralized, multi-party data sets to train AI models without having to pool data. This approach will complement Sanofi’s developments oncology.

Last Month:

Congrats to Owkin and Sanofi for landing DealForma’s November 2021 Top Biopharma Deal. Last month’s Deal of the Month was Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

28,664

Deal Profiles

18,893

Funding Rounds

32,123

Company Profiles

22,077

Product Profiles

119K+

Clinical Trials

3,967

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.